Lilly’s one-dose gene editor cuts LDL by 62% in early trial
TL;DR Summary
Eli Lilly’s high-dose, one-time gene-editing therapy VERVE-102 lowered LDL cholesterol by 62% in a Phase 1 trial, with no treatment-related serious adverse events, signaling potential for a single-shot approach to prevent heart disease after Lilly’s $1 billion acquisition of Verve Therapeutics.
- Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study statnews.com
- One-and-Done Heart Disease Prevention? Scientists Show It May Be Possible. The New York Times
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia investor.lilly.com
- Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors Fierce Biotech
- Gene Editing: A ‘One-Time’ Treatment for CVD? Medscape
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
90%
403 → 41 words
Want the full story? Read the original article
Read on statnews.com